Portolan Capital Management, LLC
Position in CADL — Candel Therapeutics, Inc.
CIK 1350290
BOSTON, MA
Position in CADL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$14,182,192
+$4,603,369 QoQ
Shares Held
2,894,325
+70.7% QoQ
Ownership
3.95%
of shares outstanding
% of Portfolio
0.77%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Portolan Capital Management, LLC holds $19,362,117 across 2 Biotechnology names. CADL ranks #1 (73.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CADL |
Candel Therapeutics, Inc.
This page
|
2,894,325 | $14,182,192 | |
| 2 | TLX |
Telix Pharmaceuticals Ltd
|
541,267 | $5,179,925 |
All Filings in CADL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,182,192 | 2,894,325 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $9,578,823 | 1,695,367 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,059,124 | 1,384,142 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $8,205,943 | 1,621,728 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $4,978,689 | 881,184 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $6,542,506 | 753,745 | Shares | Sole | 2025-02-13 | |
| No filing history on record for this holder in this stock. | ||||||